New medication plus chemotherapy after liver cancer surgery

Plain-English translation of NCT07337460 on ClinicalTrials.gov ↗ · Source last updated January 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a combination treatment for people who have had surgery to remove hepatocellular carcinoma (liver cancer) and are at high risk of the cancer returning. The treatment combines a medication called Icaritin that you take by mouth with a chemotherapy infusion delivered directly into the blood vessels feeding the liver. Researchers want to see if this combination can reduce the chance of cancer coming back and improve survival.

Liver cancer often comes back after surgery, especially in people with aggressive tumors or other high-risk features. This trial exists to find better ways to prevent recurrence and improve outcomes for people like you who have had surgery but face a higher chance that the cancer could return.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with hepatocellular carcinoma (liver cancer) and had surgery to remove it within the past 8 weeks
your surgery achieved complete removal of the cancer with clear margins and no remaining disease on imaging
you have at least one high-risk feature for cancer recurrence, such as a large tumor, cancer cells in blood vessels, multiple tumors, or an aggressive tumor grade
your overall health is good enough to tolerate chemotherapy (ECOG score 0–1)
your liver, kidney, and bone marrow function are adequate based on recent blood tests

You likely don't qualify if…

you have evidence that cancer has spread outside the liver or has come back after surgery
you have already received chemotherapy, targeted therapy, immunotherapy, or other cancer treatments before surgery
you have received other types of treatment (like TACE) after your surgery
you are pregnant or planning to become pregnant
you have severe liver disease (advanced cirrhosis) or significantly impaired kidney or bone marrow function

What participation looks like

You will begin the medication within 2 weeks after your first chemotherapy infusion, which happens 4–8 weeks after surgery. You will take the medication by mouth twice daily for three months. You may receive up to two chemotherapy infusions delivered directly into the liver blood vessels, spaced about 3 weeks apart. Throughout the study, you will have follow-up visits every 8–12 weeks for up to one year, including imaging scans (CT or MRI), blood tests, liver function tests, heart monitoring, and assessments of side effects and quality of life.

AI-generated summary from trial data · Jun 27, 2026 · Not medical advice

Trial locations(1 site)

China

Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu